AIM ImmunoTech has reported positive initial pilot study data from its ongoing Expanded Access Program (EAP or AMP-511), a Phase III clinical trial of an investigational drug, Ampligen, for long Covid. 

The multicentre, prospective, open-label trial is analysing Ampligen for treating patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). 

It was modified in October 2020 to include patients who have had Covid-19 following virus clearance. These patients showed chronic fatigue-like symptoms called post-Covid conditions. 

Four post-Covid patients were treated in the amendment ‘pilot’ programme. 

Under the amendment, subjects are required to meet the 1988 or 1994 CDC Case Definition for CFS.

They receive intravenous (IV) dose of Ampligen twice a week and if well-tolerated, the dose will escalate up to 400mg.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to findings from this uncontrolled trial, subjects had statistically significant improvements in chronic fatigue following Ampligen treatment. 

The company is working towards submitting an investigational new drug (IND) application to the Food and Drug Administration for a Phase II controlled trial of Ampligen given for 12 weeks to treat post-Covid conditions. 

Ampligen modulates the immune system and has shown antiviral activity.

AIM ImmunoTech CEO Thomas Equels said: “The positive preliminary data demonstrated in this pilot study bolsters our confidence in the potential of Ampligen as we continue to drive its development as a potential therapeutic for the treatment of long Covid. 

“With the positive preliminary results demonstrated to date we remain, now more than ever, steadfast in our mission to bring an effective therapeutic option to those in need.”

In May this year, the company provided an update on its ongoing efforts to develop an effective treatment for long Covid with Ampligen.